Ben Bronstein - Net Worth and Insider Trading

Ben Bronstein Net Worth

The estimated net worth of Ben Bronstein is at least $73,644 dollars as of 2024-05-20. Ben Bronstein is the Director of Aldeyra Therapeutics Inc and owns about 18,644 shares of Aldeyra Therapeutics Inc (ALDX) stock worth over $73,644. Details can be seen in Ben Bronstein's Latest Holdings Summary section.

Disclaimer: The insider information is derived from SEC filings. The estimated net worth is based on the assumption that Ben Bronstein has not made any transactions after 2019-09-17 and currently still holds the listed stock(s).

Transaction Summary of Ben Bronstein

To

Ben Bronstein Insider Ownership Reports

Based on ownership reports from SEC filings, as the reporting owner, Ben Bronstein owns 1 companies in total, including Aldeyra Therapeutics Inc (ALDX) .

Click here to see the complete history of Ben Bronstein’s form 4 insider trades.

Insider Ownership Summary of Ben Bronstein

Ticker Comapny Transaction Date Type of Owner
ALDX Aldeyra Therapeutics Inc 2019-09-17 director

Ben Bronstein Latest Holdings Summary

Ben Bronstein currently owns a total of 1 stock. Ben Bronstein owns 18,644 shares of Aldeyra Therapeutics Inc (ALDX) as of September 17, 2019, with a value of $73,644.

Latest Holdings of Ben Bronstein

Ticker Comapny Latest Transaction Date Shares Owned Current Price ($) Current Value ($)
ALDX Aldeyra Therapeutics Inc 2019-09-17 18,644 3.95 73,644

Holding Weightings of Ben Bronstein


Ben Bronstein Form 4 Trading Tracker

According to the SEC Form 4 filings, Ben Bronstein has made a total of 1 transactions in Aldeyra Therapeutics Inc (ALDX) over the past 5 years, including 1 buys and 0 sells. The most-recent trade in Aldeyra Therapeutics Inc is the acquisition of 1,700 shares on September 17, 2019, which cost Ben Bronstein around $9,945.

Insider Trading History of Ben Bronstein

No transactions are available. GuruFocus only tracks and displays the purchase and sale of non-derivative security in open market or private transactions from SEC filings with the transaction code of P or S.
Total 0
  • 1
Only the transactions in Open Market or Private Sale at the market prices are included. Other transactions such as conversion of derivative security or exercise of options are not included. Insiders are limited to only officers and/or directors of the company.

Ben Bronstein Trading Performance

GuruFocus tracks the stock performance after each of Ben Bronstein's buying transactions within different timeframes. To be detailed, the average return of stocks after 3 months bought by Ben Bronstein is -10.62%. GuruFocus also compares Ben Bronstein's trading performance to market benchmark return within the same time period. The performance of stocks bought by Ben Bronstein within 3 months outperforms 0 times out of 2 transactions in total compared to the return of S&P 500 within the same period.

You can select different timeframes to see how Ben Bronstein's insider trading performs compared to the benchmark.

Please note GuruFocus will not track the insiders’ transaction performance if he/she does not have buying transactions.

Performance of Ben Bronstein

Average Return

Average return per transaction

Outperforming Transactions

2 out of 2 outperforming transactions.
Each transaction is measured over a period and compared to .
1 Month 3 Months 6 Months 1 Year 2 Years 3 Years
Return(%) 2.39
Relative Return to S&P 500(%) 1.94

Ben Bronstein Ownership Network

Ownership Network List of Ben Bronstein

No Data

Ownership Network Relation of Ben Bronstein


Ben Bronstein Owned Company Details

What does Aldeyra Therapeutics Inc do?

Who are the key executives at Aldeyra Therapeutics Inc?

Ben Bronstein is the director of Aldeyra Therapeutics Inc. Other key executives at Aldeyra Therapeutics Inc include 10 percent owner Perceptive Life Sciences Master Fund Ltd , Chief Development Officer Stephen Machatha , and director & President and CEO Todd C Brady .

Aldeyra Therapeutics Inc (ALDX) Insider Trades Summary

Over the past 18 months, Ben Bronstein made no insider transaction in Aldeyra Therapeutics Inc (ALDX). Other recent insider transactions involving Aldeyra Therapeutics Inc (ALDX) include a net sale of 2,074,234 shares made by Perceptive Life Sciences Master Fund Ltd , a net sale of 41,305 shares made by Stephen Machatha , and a net sale of 26,402 shares made by Bruce Greenberg .

In summary, during the past 3 months, insiders sold 250,945 shares of Aldeyra Therapeutics Inc (ALDX) in total and bought 682,265 shares, with a net purchase of 431,320 shares. During the past 18 months, 3,007,444 shares of Aldeyra Therapeutics Inc (ALDX) were sold and 682,265 shares were bought by its insiders, resulting in a net sale of 2,325,179 shares.

Aldeyra Therapeutics Inc (ALDX)'s detailed insider trading history can be found in Insider Trading Tracker table.

To

Aldeyra Therapeutics Inc Insider Transactions

No Available Data

Ben Bronstein Mailing Address

Above is the net worth, insider trading, and ownership report for Ben Bronstein. You might contact Ben Bronstein via mailing address: 15 New England Executive Park, Burlington Ma 01803.

Discussions on Ben Bronstein

No discussions yet.